首页> 外文期刊>Applied cancer research. >Prognostic utility of epidermal growth factor receptor (EGFR) expression in prostatic acinar adenocarcinoma
【24h】

Prognostic utility of epidermal growth factor receptor (EGFR) expression in prostatic acinar adenocarcinoma

机译:表皮生长因子受体(EGFR)表达在前列腺腺泡腺癌中的预后作用。

获取原文
           

摘要

Background Epidermal growth factor receptor (EGFR) is potential prognostic biomarker expressed in many human cancers. Prognostic significance of EGFR immunohistochemical expression has not been established in prostatic acinar adenocarcinoma, therefore we aimed to evaluate the frequency of expression of EGFR in prostatic adenocarcinoma and its association with other prognostic parameters. Methods The study included 123 cases of biopsy proven prostatic acinar adenocarcinoma treated at Liaquat National hospital, Karachi from January 2013 till December 2017. Paraffin blocks of all cases were retrieved; sections were cut and stained with haematoxylin and eosin. Pathologic characteristics including tumor quantification, WHO grade group, gleason score, perineural and lymphovascular invasion were evaluated. EGFR immunohistochemistry (IHC) was performed on all tissue blocks. Results Mean age of the patients included in the study was 69.05?±?8.68?years. High gleason scores i.e. 8 & 9 were noted in 22% (27 cases) and 22.8% (28 cases) respectively. Similarly, 22.8% (28 cases) showed WHO grade group 5. 52.8% (65 cases) had ?50% tissue involvement by carcinoma and perineural invasion was seen in 37.4% (46 cases). Positive EGFR expression was noted in 18.7% (23 cases), while 81.3% (100 cases) showed negative EGFR expression. Significant association of EGFR expression was noted with gleason score ( p -value?=??0.001), WHO grade (p?=??0.001), tumor quantification ( p =?0.007) and perineural invasion (p?=??0.001). Moreover, significant association of EGFR expression was also seen with disease recurrence and Her2neu over expression. Patients with low gleason scores (score 6 and 7) and lower grade group (1, 2 & 3) were less likely to have positive EGFR expression as compared to patients with high gleason score (score 9) and higher grade group (5). Similarly, patients with perineural invasion were more likely to have positive EGFR expression. Conclusion We found a relatively low EGFR expression in our patients with prostatic adenocarcinoma; however, its association with poor prognostic parameters like high gleason score, higher grade group, perineural invasion, higher tissue involvement by cancer and disease recurrence signifies its importance as a prognostic parameter in prostatic acinar adenocarcinoma.
机译:背景表皮生长因子受体(EGFR)是在许多人类癌症中表达的潜在预后生物标志物。尚未在前列腺腺泡腺癌中确定EGFR免疫组织化学表达的预后意义,因此我们旨在评估EGFR在前列腺腺癌中的表达频率及其与其他预后参数的关系。方法自2013年1月至2017年12月,在卡拉奇市利夸特国家医院对123例经活检证实为前列腺腺泡腺癌的活检病例进行了研究。切下切片并用苏木精和曙红染色。评估了病理特征,包括肿瘤定量,WHO分级组,格里森评分,神经周围和淋巴管浸润。在所有组织块上进行EGFR免疫组化(IHC)。结果纳入研究的患者平均年龄为69.05?±?8.68?岁。格里森得分较高,分别为22%(27例)和22.8%(28例),分别为8和9。同样,有22.8%(28例)显示出WHO等级组5。52.8%(65例)具有≥50%的癌组织受累,神经周浸润占37.4%(46例)。 18.7%(23例)的EGFR表达阳性,而81.3%(100例)的EGFR表达阴性。 EGFR的表达与格里森评分(p值== <0.001),WHO等级(p == <0.001),肿瘤定量(p = 0.007)和神经周围浸润(p =?)显着相关。 <0.001)。此外,还发现EGFR表达与疾病复发和Her2neu过表达显着相关。与格里森评分较高(评分9)和较高评分组(5)相比,格里森评分较低(评分6和7)和低评分组(1、2和3)的患者EGFR表达阳性的可能性较小。同样,神经周围浸润患者更可能具有阳性EGFR表达。结论我们发现前列腺腺癌患者的EGFR表达较低。然而,其与不良预后参数(如高格里森评分,较高等级的组,神经周浸润,癌的组织累及率更高和疾病复发)的相关性表明其作为前列腺腺泡腺癌的预后参数的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号